Investors

Press Releases

Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
Endonovo Pending Agreement to Develop Telehealth Division
Endonovo Launches SofPulse® into the Veterans Administration
Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan
Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery
Endonovo Announces Distribution Agreement with Academy Medical
Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg
Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
Endonovo Partners with International Distributor for SofPulse® Line
New Details on Endonovo’s Spin-Off of SofPulse, Inc.
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company
Endonovo Targets Dept. of Defense, VA & Federal Contracts
Endonovo Announces Advancement of International “Go to Market” Initiative
Endonovo Announces Plans for Spin-off of Medical IP and Assets
Endonovo Launches Telehealth Initiative
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS
Endonovo Therapeutics Issues Corporate Update
Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
Endonovo Therapeutics Issues Shareholder Update
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
Endonovo Therapeutics Introduces Support of SofPulse® With A New Ancillary Multi-Use Patient Brace From Protex
Endonovo Therapeutics Begins Process For Medical Reimbursements
Endonovo Therapeutics Announces collaborating with a Stanford University sponsored Orthopedic Shoulder and Knee Study
Endonovo Therapeutics announces its collaboration with Major Universities for the Evaluation of SofPulse® for Orthopedic Surgeries
Endonovo Therapeutics Reduces Debt
Endonovo Therapeutics Expands SofPulse® Sales to Plastic Surgery Centers
Endonovo Therapeutics Announces First SofPulse® Sales to a Veterans Medical Center
Endonovo Therapeutics Announces Issuance of Broad Patent Covering Electromagnetic Treatment of Multiple Sclerosis
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke
Endonovo Therapeutics Provides SofPulse® To All NFL Teams
Endonovo Therapeutics Announces Effective Date of Previously Announced Reverse Split of Common Stock
Endonovo Therapeutics Announces Reverse Stock Split - UPDATE
Endonovo Therapeutics Announces Reverse Stock Split
Endonovo Therapeutics Reports Third Quarter 2019 Results
Endonovo Therapeutics Announces Reverse Stock Split
Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO
Endonovo Partners with Veterans Healthcare Supply Solutions, Appoints Samir Awad, M.D., to Scientific Advisory Board
Endonovo Therapeutics Appoints Dr. Geoffrey Abrams of Stanford University to Its Scientific Advisory Board
Endonovo Therapeutics Announces Second Quarter Results
Endonovo Therapeutics Inc. Featured in Exclusive NetworkNewsWire Broadcast
Endonovo Therapeutics Appoints Dr. Peter Novak to its Scientific Advisory Board
Endonovo Therapeutics Appoints Dr. Steven Levin of Johns Hopkins University to Its Scientific Advisory Board
Endonovo Therapeutics Announces National Rollout of SofPulse® Post-Operative Opioid Alternative into Hospitals
Coverage Initiated for Endonovo Therapeutics via NetworkNewsWire
Endonovo Therapeutics and Veterans Healthcare Supply Solutions Announce Distribution Agreement
Endonovo Therapeutics Appoints Dr. Roc Alan McCarthy as a Scientific Advisory Board Member
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
Endonovo Therapeutics Hires David Clark as Vice President of Sales
Endonovo Therapeutics Hires Nevena Zubcevik of Harvard Medical School as Chief Medical Officer
Endonovo Therapeutics Provides Corporate Update
Endonovo Therapeutics Announces Partnership with Second Hospital
Endonovo Therapeutics Granted Trademarks for WoundPulse and OrthoHalo
Endonovo Therapeutics Partners with SunMED Medical Systems
Endonovo Therapeutics Announces New Website Launch
Endonovo Therapeutics Files Lawsuit against KVP International Inc., Orthocor Medical Inc., and Careus Corp. for Patent Infringement
Endonovo Therapeutics Issues Shareholder Letter and Update
Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital
Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
Endonovo Expands SofPulse Commercialization
Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company
Endonovo Therapeutics Announces Complimentary New Product
Endonovo Therapeutics Provides Update on Liver Study
Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical™ System
Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy
Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical™ SofPulse®
Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico
Endonovo Reports Positive Results in Critical Limb Ischemia Study Using Non-Invasive Medical Device
Endonovo Reports Pre-Clinical Data Demonstrating Immunotronics™ Reduced Infarct Size and Inhibited Fibrosis following Myocardial Infarction
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
Endonovo Therapeutics Provides Corporate Update and 2018 Outlook
Endonovo Therapeutics Engages ShareIntel, A Leader In Shareholder Intelligence Services To Investigate Market Maker and Clearing Firm Irregularities
Endonovo Therapeutics Provides Update on Acquisition of PEMF Assets, Clinical Pipeline and Pre-Clinical Study
Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit
Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical
Endonovo Therapeutics Provides Update on Pre-Clinical Studies
Endonovo Therapeutics, Inc. and Kodiak Capital Group, LLC Announce Settlement and Dismissal of Lawsuit
Endonovo Therapeutics Issues Open Letter and Update to Its Shareholders
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Kidney Disease
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device for Treatment of Critical Limb Ischemia
Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Endonovo Therapeutics (ENDV): Targeting $20+ Billion Market for In Vitro ADME and Toxicology Testing
Endonovo Therapeutics Announces Registration Statement on Form S-1 has been Declared Effective
Endonovo Therapeutics Issues Corporate Update
Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules
Endonovo Therapeutics Announces New Round of Financing
Endonovo Therapeutics Announces Binding Letter of Intent to Acquire Rio Grande Neurosciences, Inc.
Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome
Endonovo Therapeutics Awarded Preliminary Injunction Against Kodiak Capital et al
Endonovo Therapeutics Provides Update on Variable Convertible Notes
Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New York
Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells
Endonovo Therapeutics Provides Corporate Update and 2016 Outlook
Endonovo Therapeutics Retains Holland & Knight to File for Orphan Drug Designation
Endonovo Therapeutics Buys Back Convertible Note From Lender Avoiding Any Immediate Dilution
Endonovo Therapeutics Developing Next-Generation Cell Therapy for Acute and Chronic Graft-Versus-Host Disease Using Cell-Enhancing Cytotronics Platform
Endonovo Therapeutics Files Patent Application on Cell Therapy Created Using Its Proprietary Cell-Enhancing Cytotronics Platform
Endonovo Therapeutics Announces Immunotronic and Cytotronic Platforms
Endonovo Therapeutics Announces Method for Large Scale Expansion of Cord Blood
Endonovo Therapeutics Announces Corporate Patent Licensing Program
Endonovo Therapeutics Targets Non-Invasive Treatment for Acute and Chronic Inflammatory Conditions of the Liver
Endonovo Therapeutics Enters into a $3 Million Equity Purchase Agreement with Kodiak Capital Group, LLC
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment
Endonovo Therapeutics Files Patent on Bioelectronic Technology, Devices and Therapies
Endonovo Therapeutics Developing Non-Invasive Bioelectronic Therapy for Urinary Incontinence
Endonovo Therapeutics to Develop Next Generation, Off-The-Shelf, Cell Free Regenerative Products
Endonovo Therapeutics Affects 1-for-100 Reverse Stock Split
Endonovo Therapeutics Changes Ticker Symbol to ENDV
Endonovo Therapeutics Signs Funding Agreement for $10 Million
Hanover Portfolio Acquisitions Changes Its Name to Endonovo Therapeutics
Hanover Portfolio Acquisitions Acquires Biotechnology Company Using Time-Varying Electromagnetic Frequencies for Regenerative Medicine
Hanover Completes Acquisition of Israeli Technology Incubator
Hanover Portfolio Acquisitions Signs Letter of Intent to Acquire Israeli Technology Incubator
Hanover Portfolio Acquisitions Signs Letter of Intent to Acquire Tigga Studios Serving Multi-Billion Dollar Mobile App Market
Hanover to Monetize Underutilized Patents by Converting Them Into Royalty Generating Assets
Hanover Portfolio Acquisitions to Pursue $40 Billion Equestrian Market Through Technology Commercialization Deal
Hanover Portfolio Acquisitions to Present at FSX Investment Conference in Dallas on February 8, 2013
IP Resources Arranges Licensing Deal for New Stem Cell Skin Care Product on Forbes List of Top 10 Fashion and Beauty Startups for 2012
Hanover Portfolio Acquisitions Signs Letter of Intent to Acquire Pain Management Medical Device Company Addressing Estimated $2.5 Billion U.S. Market
IP Resources Set to Unlock Value in the $237 Billion Intellectual Property Licensing Market
IP Resources International Sponsors Microsoft Alumni Foundation Annual Celebration
RSS